Literature DB >> 10159895

The dilemma of Jehovah's Witness children who need blood to survive.

A Catlin.   

Abstract

Medical researchers must continue to develop and test non-blood oxygen-transport products. Resources provided by the Jehovah's Witness Hospital Assistance Line must be consulted. Sickle cell researchers must continue to test non-blood treatment. Information about non-blood treatments must be disbursed. Ways to enhance parental comfort as the laws further and further support children's best interest must be provided. Information regarding cultural diversity must be disseminated. Hospitals and healthcare agencies that have not done so must institute the use of ethics consulting or ethics committees. Nurse ethicists must continue development of the role of educating staff; mediation, arbitration and negotiation; problem solving; obtaining legal opinion; providing patient, family, or staff advocacy; and helping to reduce suffering on the part of the providers. Difficult ethical decisions should continue to be debated. Were the staff X Med Center correct in overriding parental wishes and breaking tenets of their faith? In the doctor's, nurse's, lawyer's, and judge's view they were. The child, now eight years old, is alive and well. The stroke resolved, and imminent death averted. The parents' and child's views are not presently available. Whether the family is suffering from the child's loss of his relationship with God, or are secretly relieved in their hearts that they are not, like Rita Swan, mourning their dead son, is unknown. What is known, is that this was a difficult case for all involved, and that such cases will continue to present themselves in the future.

Entities:  

Keywords:  Professional Patient Relationship; Religious Approach

Mesh:

Year:  1996        PMID: 10159895     DOI: 10.1007/bf00056549

Source DB:  PubMed          Journal:  HEC Forum        ISSN: 0956-2737


  27 in total

Review 1.  Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations.

Authors:  K Ohene-Frempong
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

2.  Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia.

Authors:  M Feola; J Simoni; R Angelillo; Z Luhruma; M Kabakele; M Manzombi; M Kaluila
Journal:  Surg Gynecol Obstet       Date:  1992-05

3.  The law should protect all children.

Authors:  R Swan
Journal:  J Christ Nurs       Date:  1987

4.  Challenging medical authority. The refusal of treatment by Christian Scientists.

Authors:  L May
Journal:  Hastings Cent Rep       Date:  1995 Jan-Feb       Impact factor: 2.683

5.  When to transfuse blood in sickle cell disease? Lessons from Jehovah's Witnesses.

Authors:  E S Pearlman; S K Ballas
Journal:  Ann Clin Lab Sci       Date:  1994 Sep-Oct       Impact factor: 1.256

6.  Management of severe anemia in a pediatric Jehovah's Witness patient.

Authors:  R K Spence
Journal:  Crit Care Med       Date:  1995-02       Impact factor: 7.598

7.  Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.

Authors:  E Fibach; P Prasanna; G P Rodgers; D Samid
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

8.  Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease.

Authors:  A K al-Momen
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

9.  Successful use of recombinant human erythropoietin in a Jehovah's Witness with a thermal injury.

Authors:  E A Deitch; D Guillory; N Cruz
Journal:  J Burn Care Rehabil       Date:  1994 Jan-Feb

10.  Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.

Authors:  E Voskaridou; V Kalotychou; D Loukopoulos
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

View more
  1 in total

1.  Introduction: children and consent to treatment.

Authors:  James Stacey Taylor
Journal:  HEC Forum       Date:  2013-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.